Qualifying Therapeutic Discovery Project Grants for the State of Georgia
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Abeome Corporation | Discovery of monocional antibodies for cancer therapeutic and biomarker development | $ 244,479.24 | |
| Access Product Marketing, LLC | Project APM01050 - Patient friendly delivery of glucagon for emergency treatment of severe hypoglycemia | $ 207,410.00 | $ 37,069.25 |
| AerovectRx Corporation | AerovectRx disposable drug cartridge (DDC) compatibility and stability | $ 32,200.00 | $ 90,800.00 |
| Alaven Pharmaceutical LLC | CALM-UC Clinical Assessment of Low Dose Mesalamine in Uncerative Colitis | $ 244,479.25 | |
| Alimera Sciences Inc. | Iluvien for the Treatment of Diabetic Macular Edema | $ 244,479.25 | |
| ALTEA THERAPEUTICS | ENOXPARIN SODIUM PASSPORT ® SYSTEM | $ 244,479.25 | |
| ALTEA THERAPEUTICS CORP | EXENATIDE PASSPORT(R)STEM | $ 244,479.25 | |
| Altiris Therapeutics, Inc. | ALT-118 | $ 244,479.25 | |
| Apeliotus Vision Science, Inc. | Diagnostic for Age-Related Macular Degeneration | $ 96,546.00 | $ 147,933.25 |
| Argent Diagnostics Inc | High Sensitivity Nano-Optical Method to Detect Measles Virus | $ 6,222.00 | $ 28,904.50 |
| Atlanta Catheter Therapies, Inc (ACT) | Prototype development and Pre-Clinical testing of Occlusion Perfusion Catheter | $ 160,112.00 | $ 84,367.24 |
| Axona Inc. (dba AxoTect, Inc.) | Calpain inhibitors for Cancer Related Neuropathies | $ 64,939.50 | $ 87,500.00 |
| Cardiac regeneration Technologies, LLC | CardioGold Project | $ 174,527.00 | $ 69,952.25 |
| CardioMEMS Inc | CardioMEMS Heart Failure System (CardioMEMS HF-system) | $ 244,479.25 | |
| Carticept Medical, Inc | Navigator™ Delivery System | $ 244,479.24 | |
| Cell Constructs Inc | Autologous Stem Cell Therapy Dressing for Chronic Wounds | $ 15,787.50 | $ 108,808.00 |
| CeloNova BioSciences, Inc. | Safety and Efficacy of Embozene Microspheres for Uterine Artery Embolization for SUF | $ 244,479.25 | |
| CeloNova BioSciences, Inc. | Safety and Efficacy of a Newly Designed Coronary Stent Coated with Polyzene-F | $ 244,479.25 | |
| CeloNova BioSciences, Inc. | Target Drug Delivery Device: OncoZene Drug Eluting Microspheres | $ 244,479.25 | |
| Celtaxsys Inc | Chemorepulsion Project | $ 244,479.24 | |
| CorMatrix Cardiovascular Inc | ECM Emulsion Injection Therapy to Treat Myocardial Ischemia | $ 244,479.24 | |
| CorMatrix Cardiovascular Inc | Reduction of Postoperative Atrial Fibrillation using Co-Matrix ECM | $ 170,526.57 | $ 73,952.67 |
| CorMatrix Cardiovascular Inc | Tissue Regenerating ECM for Vascular Applications | $ 108,602.13 | $ 135,877.11 |
| CorMatrix Cardiovascular Inc | New method to decellularize and sterlize Xenografts for optimized host integration | $ 220,709.83 | |
| CorMatrix Cardiovascular Inc | Drug-eluting ECM for Pericardial Reconstruction | $ 213,668.94 | |
| Effcon Laboratories Inc | Alcohol Abuse Treatment | $ 2,730.00 | $ 167,775.00 |
| Effcon Laboratories, Inc. | Glaucoma Project | $ 76,540.00 | $ 167,939.25 |
| Effcon Laboratories, Inc. | Lice Project | $ 8,190.00 | $ 236,289.25 |
| Effcon Laboratories, Inc. | Dystonia Project | $ 22,800.50 | $ 221,678.75 |
| Envisionier Medical Technologies, Inc | endogo®HD, endoscopic imaging system | $ 159,992.00 | $ 48,504.50 |
| Femasys Inc. | FemVue Systems | $ 244,479.25 | |
| Femasys Inc. | FemBloc Permanent Contraceptive System | $ 244,479.25 | |
| GeneCure LLC | Development of therapeutic HIV vaccines | $ 244,479.24 | |
| GeoVax, Inc | HIV/AIDS Vaccine | $ 244,479.24 | |
| Glycosensors and Diagnostics, LLC | High-specificity affinity reagents for N-glycosylation site mapping and glycomics | $ 33,307.98 | $ 84,709.16 |
| Guided Therapeutics, Inc. | Cost Effective Noninvasive Cervical Cancer Detection System | $ 244,479.24 | |
| Health Discovery Corporation | Health Discovery Corporation's SVM and RFE-SVM Technology | $ 109,323.02 | $ 135,156.23 |
| ICON Interventional Systems, Inc. | ICON® NULOY® Drug Eluting Stent (DES) Platform | $ 244,479.25 | |
| Iconic Therapeutics, Inc. | Iconic Therapeutics, Inc.: Development of I-con1 | $ 244,479.25 | |
| Inhibikase Therapeutics Inc | Host-targeted antiviral for seasonal and pandemic influenza | $ 76,207.50 | $ 168,271.74 |
| Inhibikase Therapeutics Inc | Antiviral treatment for progressive multifocal leukoencephalopathy | $ 61,799.50 | $ 182,679.74 |
| Inhibikase Therapeutics Inc | Antiviral treatment for polyomavirus-associated nephropathy | $ 61,799.50 | $ 182,679.74 |
| INHIBITEX, INC | FV-100 | $ 244,479.24 | |
| INHIBITEX, INC | INX-189 | $ 244,479.24 | |
| InVasc Therapeutics, Inc | INV-140 Series | $ 137,557.00 | $ 106,922.25 |
| LEXICOR MEDICAL TECHNOLOGY, LLC | NEBA-M(NEUROPSYCHIATRIC EEG-BASED ASSESSMENT AID-Major Depressive Disorder) | $ 244,479.25 | |
| Lexicor Medical Techonology LLC | NEBA (neuropsychiatric eeg-based ADHD assessment Aid | $ 244,479.24 | |
| Luminomics Inc | Degenerative Disease models in zebrafish | $ 184,394.18 | $ 60,085.07 |
| MD Innovate, Inc | PneumoniaCheck-A Therapeutic Discovery Project | $ 244,479.25 | |
| Metabolic Testing Services, Inc. | Metabolic Testing for Early Detection & Treatment of Heart Disease | $ 244,479.24 | |
| MiMedx Group, Inc. | CollaFix Therapeutic Delivery | $ 244,479.25 | |
| NeurOp, Inc | Neuroprotection by pH Sensitive Antagonists to the NMDA NR2B Receptor | $ 198,809.00 | $ 45,670.25 |
| Revogenex, Inc. | RVX-108 (CDP-CB) IND 105,579 Chlorideazepoxide Hydrochloride | $ 244,479.25 | |
| Revogenex, Inc. | RVX-100 (L-HS) IND 105,364 Hysocyamine Sulfate | $ 244,479.25 | |
| Revogenex, Inc. | RVX-109 (TRML) Tramadol Hydrochloride for Injection (IV) | $ 204,277.25 | $ 40,202.00 |
| Salutria Pharmaceuticals LLC | Development of Succinobucol to Reduce Cardiovascular Risk in Type 2 Diabetes Patients | $ 244,479.24 | |
| Sanuwave Inc | dermaPace FDA IDE study for treating chrinic diabetic Foot ulcers | $ 244,479.24 | |
| Sebacia, Inc | Sebacia Acne Therapy | $ 244,479.24 | |
| Serrg Savannah Inc | CB-01-02/01 (Cosmo) | $ 5,241.50 | |
| Serrg Savannah Inc | PTK 0796-CSSSI-0804 | $ 26,206.50 | |
| Serrg Savannah Inc | NXL 103/2002 (Novexel) | $ 20,965.00 | |
| Serrg Savannah Inc | GSK TOC110978 | $ 7,748.50 | |
| SoloHealth, Inc | SoloHealth Health and Wellness Kiosk | $ 244,479.25 | |
| Southeast Regional Research Group Inc | CB-01-02/01(Cosmo) | $ 2,305.00 | |
| Southeast Regional Research Group Inc | PTK 0796-CSSSI-0804 | $ 13,825.00 | |
| Southeast Regional Research Group Inc | GSK TOC110978 | $ 4,608.50 | |
| Southeast Regional Research Group, Inc | CE06-300(Cempra ABSSSI) | $ 9,216.50 | |
| Southeast Regional Research Group, Inc. | CVRX | $ 18,433.00 | |
| Tissue Regeneration Technologies, LLC | Software | $ 126,172.00 | $ 118,307.25 |
| Transfusion & Transplantation Technologies INC. | Aegis Automated Blood Analyzer | $ 198,769.50 | $ 45,709.75 |
| Velocity Medical Solutions, LLc | Imaging for Treatment Assessment and Response to Cancer Therapies | $ 244,479.25 | |
| Visioneering Technologies, Inc | Development of a Novel Therapeutic to Treat and Prevent Myopia | $ 244,479.25 | |
| Zenda Technologies, Inc. | DETECT - an immersive solution for neuropsychological testing in a primary care setting | $ 167,354.00 | $ 77,125.25 |
| Zirus Inc | The Development of Broadly Active and Orally Bioavailable Antiviral Drugs | $ 244,479.24 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-12
